AstraZeneca has secured the last piece to a global puzzle of licensing agreements with Ionis Pharmaceuticals for the rare heart disease drug eplontersen. | AstraZeneca has secured the last piece to a global puzzle of licensing agreements with Ionis for the rare heart disease drug eplontersen. The partners have now extended a global licensing deal for the transthyretin amyloidosis (ATTR) therapy to Latin America, which means another $20 million for Ionis.
